Allopurinol, an inhibitor of xanthine oxidase, has been reported or suggested to increase HGPRT activity in patients with inflammatory bowel disease (IBD) and ALL [91,92]. This evidence concerns the gene HPRT1 and acute lymphoblastic leukemia.